摘要
目的观察利格列汀联合司美格鲁肽治疗2型糖尿病(T2DM)的效果。方法将2020年3月至2023年2月我院收治的100例T2DM患者分为两组。对照组采用利格列汀治疗,观察组采用利格列汀联合司美格鲁肽治疗。比较两组的治疗效果、血糖水平及不良反应。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组的FPG、2hPG低于对照组,FC-P、2hC-P高于对照组(P<0.05)。两组的不良反应发生率比较无统计学差异(P>0.05)。结论利格列汀联合司美格鲁肽治疗T2DM的效果较好,可维持患者血糖水平稳定,调节胰岛功能。
Objective To observe the effect of linagliptin combined with semaglutide in the treatment of type 2 diabetes mellitus(T2DM).Methods 100 T2DM patients admitted to our hospital from March 2020 to February 2023 were divided into two groups.The control group was treated with linagliptin,and the observation group was treated with linagliptin combined with smectiglutide.The treatment effect,blood glucose level and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the FPG and 2hPG of the observation group were lower than those of the control group,and the FC-P and 2hC-P were higher than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Linagliptin combined with semaglutide has better effect in the treatment of T2DM,which can maintain the stability of blood glucose levels,and regulate the pancreatic islet function.
作者
石勇芳
王丹萍
邓飞
SHI Yongfang;WANG Danping;DENG Fei(Department of Endocrinology and Metabolism,Luohe First People's Hospital/Luohe Central Hospital,Luohe 462300,China)
出处
《临床医学工程》
2024年第1期29-30,共2页
Clinical Medicine & Engineering
基金
河南省医学科技攻关计划联合共建项目(LHGJ20200896)。